MML Investors Services LLC Grows Stock Holdings in Elanco Animal Health Incorporated (NYSE:ELAN)

MML Investors Services LLC raised its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 31.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 15,454 shares of the company’s stock after purchasing an additional 3,692 shares during the quarter. MML Investors Services LLC’s holdings in Elanco Animal Health were worth $227,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Benjamin F. Edwards & Company Inc. increased its position in shares of Elanco Animal Health by 337.7% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,764 shares of the company’s stock valued at $26,000 after purchasing an additional 1,361 shares during the last quarter. ORG Wealth Partners LLC bought a new position in Elanco Animal Health during the third quarter valued at $29,000. nVerses Capital LLC bought a new position in Elanco Animal Health during the second quarter valued at $32,000. AM Squared Ltd purchased a new stake in shares of Elanco Animal Health in the third quarter valued at $34,000. Finally, Quarry LP bought a new stake in shares of Elanco Animal Health in the 2nd quarter worth about $40,000. 97.48% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages recently commented on ELAN. Leerink Partners assumed coverage on shares of Elanco Animal Health in a report on Monday, December 2nd. They set a “market perform” rating and a $14.00 price target on the stock. UBS Group started coverage on Elanco Animal Health in a research note on Monday, December 9th. They set a “buy” rating and a $18.00 target price on the stock. Stifel Nicolaus reissued a “buy” rating and set a $20.00 price target on shares of Elanco Animal Health in a research note on Thursday, September 19th. Morgan Stanley cut Elanco Animal Health from an “overweight” rating to an “equal weight” rating and dropped their price objective for the company from $17.00 to $15.00 in a report on Thursday, September 19th. Finally, Leerink Partnrs upgraded Elanco Animal Health to a “hold” rating in a research note on Monday, December 2nd. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, Elanco Animal Health currently has an average rating of “Hold” and a consensus price target of $16.71.

Elanco Animal Health Trading Up 1.4 %

Shares of NYSE ELAN opened at $12.05 on Friday. Elanco Animal Health Incorporated has a twelve month low of $11.40 and a twelve month high of $18.80. The firm has a market cap of $5.96 billion, a PE ratio of 30.13, a price-to-earnings-growth ratio of 2.03 and a beta of 1.41. The business has a fifty day simple moving average of $12.83 and a two-hundred day simple moving average of $13.97. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.01. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The firm had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $1.04 billion. During the same period in the previous year, the company posted $0.18 earnings per share. The firm’s quarterly revenue was down 3.6% on a year-over-year basis. Analysts expect that Elanco Animal Health Incorporated will post 0.92 earnings per share for the current fiscal year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.